Compare 8x8 Inc (EGHT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs TG Therapeutics Inc — how do they compare? 8x8 Inc trades at $2.1 (market cap $311.98M), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 26.2× 8x8 Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and TG Therapeutics Inc for 16 Days on average.
| EGHT | TGTX | |
|---|---|---|
Market Cap | $311.98M | $8.16B |
Volume | 1,639,086 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $2.76 | $59.06 |
52-Week Low | $1.59 | $26.94 |
Typical Hold Time | 16 Days | 16 Days |
Enterprise Value | $578.90M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI product growth, while analysts maintain a mixed consensus with a $19.77 price target representing significant upside potential.
The stock presents a high-risk, high-reward opportunity with strong revenue growth potential but faces challenges from negative net income and high debt levels. Key catalysts include continued earnings outperformance and AI platform adoption, while risks involve execution challenges and competitive pressures in the communications software sector.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
